Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ivax Corporation has received final approval from the FDA for its abbreviated new drug application for a 200mg dosage clozapine tablet. Clozapine is the generic equivalent of Clozaril which is marketed by Novartis for the treatment of schizophrenia.
Subscribe to our email newsletter
The drug is currently available in 100, 50, 25 and 12.5mg tablet dosage strengths. The 200mg tablet is a new dosage strength developed by Ivax to create additional dosing options.
Annual US sales for Clozaril and its generic equivalent clozapine were over $135 million for the twelve months ended September 30, 2005. Ivax currently has a market share of 53% of the total market for Clozaril and its generic equivalents.
Ivax Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and generic pharmaceuticals and veterinary products in the US and internationally.